Condensed Financial Information of Parent Company - Schedule of Parent-only Statement of Cash Flows (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Cash flows from operating activities
Net loss	$ (32,828,000)	$ (25,254,000)	$ (293,623,000)
Changes in assets and liabilities:
Net cash provided by operating activities	146,780,000	178,779,000	131,341,000
Cash flows from investing activities
Distribution from (investment in) subsidiary	0	0	0
Net cash used in investing activities	(210,498,000)	(178,733,000)	(91,617,000)
Cash flows from financing activities
Proceeds from issuance of common stock in initial public offering, net of underwriting discounts and commissions	0	0	891,793,000
Proceeds from private placement with a related party	0	0	100,000,000
Repurchases of Class A common stock	101,721,000	0	0
Payments of initial public offering issuance costs	0	0	(4,937,000)
Proceeds from exercise of stock options	9,159,000	35,021,000	5,343,000
Proceeds from early exercise of stock options	0	0	667,000
Employee taxes paid related to net share settlement of equity awards	(20,635,000)	(57,688,000)	(78,714,000)
Net cash (used in) provided by financing activities	(120,226,000)	(30,528,000)	905,817,000
Net change in cash, cash equivalents and restricted cash	(183,944,000)	(30,482,000)	945,541,000
Cash
Beginning of period	941,109,000	971,591,000	26,050,000
End of period	757,165,000	941,109,000	971,591,000
GoodRx Holdings, Inc
Cash flows from operating activities
Net loss	(32,828,000)	(25,254,000)	(293,623,000)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Equity in loss of subsidiary	32,828,000	25,254,000	293,623,000
Changes in assets and liabilities:
Other asset	80,000	(23,000)	90,000
Other current liabilities	0	(87,000)	87,000
Net cash provided by operating activities	80,000	(110,000)	177,000
Cash flows from investing activities
Distribution from (investment in) subsidiary	113,117,000	22,777,000	(914,434,000)
Net cash used in investing activities	113,117,000	22,777,000	(914,434,000)
Cash flows from financing activities
Proceeds from issuance of common stock in initial public offering, net of underwriting discounts and commissions		0	891,793,000
Proceeds from private placement with a related party		0	100,000,000
Repurchases of Class A common stock	(101,721,000)
Payments of initial public offering issuance costs		0	(4,937,000)
Proceeds from exercise of stock options	9,159,000	35,021,000	5,343,000
Proceeds from early exercise of stock options		0	667,000
Employee taxes paid related to net share settlement of equity awards	(20,635,000)	(57,688,000)	(78,714,000)
Net cash (used in) provided by financing activities	(113,197,000)	(22,667,000)	914,152,000
Net change in cash, cash equivalents and restricted cash	0	0	(105,000)
Cash
Beginning of period	5,000	5,000	110,000
End of period	$ 5,000	$ 5,000	$ 5,000